Baird Medical Investment Holdings Limited (BDMD) 10-Year Financial Performance & Capital Metrics

BDMD • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutBaird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China. The company's medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical Investment Holdings Limited was founded in 2012 and is headquartered in Guangzhou, China.Show more

Revenue $37M +17.7%
EBITDA $17M +30.6%
Net Income $12M +18.1%
EPS (Diluted) 0.49 +19.5%
Gross Margin 88.16% +1.9%
EBITDA Margin 45.42% +11.0%
Operating Margin 41.35% +9.7%
Net Margin 33.62% +0.3%
ROE 33% -3.8%
ROIC 22.57% -4.1%
Debt/Equity 0.53 +89.4%
Interest Coverage 26.55 -36.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 49.8%
✓Strong 5Y sales CAGR of 24.8%
✓Healthy 5Y average net margin of 36.9%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y24.85%

3Y10.14%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y2.17%

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg72.08%

5Y Avg72.79%

3Y Avg46.04%

Latest37.78%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	12.21M	18.12M	27.72M	35.09M	31.46M	37.04M
Revenue Growth %	-	0.48%	0.53%	0.27%	-0.1%	0.18%
Cost of Goods Sold+	1.3M	2.51M	4.54M	7.05M	4.23M	4.38M
COGS % of Revenue	0.11%	0.14%	0.16%	0.2%	0.13%	0.12%
Gross Profit+	10.91M	15.61M	23.18M	28.04M	27.23M	32.65M
Gross Margin %	0.89%	0.86%	0.84%	0.8%	0.87%	0.88%
Gross Profit Growth %	-	0.43%	0.48%	0.21%	-0.03%	0.2%
Operating Expenses+	5.3M	5.75M	9.76M	13.03M	15.37M	17.34M
OpEx % of Revenue	0.43%	0.32%	0.35%	0.37%	0.49%	0.47%
Selling, General & Admin	4.15M	5M	10.22M	10.55M	11.09M	9.96M
SG&A % of Revenue	0.34%	0.28%	0.37%	0.3%	0.35%	0.27%
Research & Development	1.16M	750.48K	1.04M	3.86M	4.27M	6.17M
R&D % of Revenue	0.09%	0.04%	0.04%	0.11%	0.14%	0.17%
Other Operating Expenses	0	0	0	0	0	1.2M
Operating Income+	5.61M	9.86M	11.92M	13.63M	11.86M	15.32M
Operating Margin %	0.46%	0.54%	0.43%	0.39%	0.38%	0.41%
Operating Income Growth %	-	0.76%	0.21%	0.14%	-0.13%	0.29%
EBITDA+	5.96M	10.47M	13.32M	15.1M	12.88M	16.82M
EBITDA Margin %	0.49%	0.58%	0.48%	0.43%	0.41%	0.45%
EBITDA Growth %	-	0.76%	0.27%	0.13%	-0.15%	0.31%
D&A (Non-Cash Add-back)	349.14K	609.55K	1.4M	1.47M	1.01M	1.51M
EBIT	5.5M	9.67M	12.76M	14.82M	11.86M	14.66M
Net Interest Income+	-89.62K	-159.47K	-151.59K	-290.72K	-284.27K	-576.36K
Interest Income	0	0	2.33K	8.55K	0	393
Interest Expense	89.62K	159.47K	153.92K	299.27K	284.27K	576.75K
Other Income/Expense	-11.46M	-283.25K	688.35K	890.15K	497.48K	-1.23M
Pretax Income+	-5.85M	9.58M	12.61M	14.52M	12.36M	14.09M
Pretax Margin %	-0.48%	0.53%	0.45%	0.41%	0.39%	0.38%
Income Tax+	1.28M	2.43M	2.42M	1.75M	1.7M	1.49M
Effective Tax Rate %	1.23%	0.74%	0.93%	0.87%	0.85%	0.88%
Net Income+	-7.18M	7.1M	11.68M	12.57M	10.55M	12.45M
Net Margin %	-0.59%	0.39%	0.42%	0.36%	0.34%	0.34%
Net Income Growth %	-	1.99%	0.64%	0.08%	-0.16%	0.18%
Net Income (Continuing)	-7.13M	7.15M	10.18M	12.77M	10.66M	12.6M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	-683.77K	-448.7K	-356.73K	-155.59K	-43.39K	101.34K
EPS (Diluted)+	-1.00	0.99	-0.02	0.02	0.41	0.49
EPS Growth %	-	1.99%	-1.02%	1.9%	17.89%	0.2%
EPS (Basic)	-1.00	0.99	-0.02	0.02	0.41	0.49
Diluted Shares Outstanding	7.19M	7.19M	7.19M	7.19M	7.58M	25.63M
Basic Shares Outstanding	7.19M	7.19M	7.19M	6.29M	7.58M	25.56M
Dividend Payout Ratio	-	-	0.46%	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.67M	13.05M	22.4M	33.76M	40.08M	61.42M
Cash & Short-Term Investments	257.08K	1.14M	3.44M	1.91M	1.63M	2.97M
Cash Only	220.45K	1.07M	3.03M	1.71M	1.51M	2.97M
Short-Term Investments	36.62K	65.11K	407.5K	197K	120.48K	0
Accounts Receivable	4.56M	8.23M	12.45M	24.76M	31.49M	46.58M
Days Sales Outstanding	136.28	165.78	163.89	257.58	365.42	459.03
Inventory	709.47K	810.07K	3.06M	1.29M	1.14M	1.3M
Days Inventory Outstanding	199.41	117.75	245.44	66.91	98.65	107.97
Other Current Assets	3.05M	620.89K	304.29K	197K	120.48K	295.75K
Total Non-Current Assets+	3.09M	3.97M	3.72M	8.85M	16.63M	16.55M
Property, Plant & Equipment	1.66M	2.84M	3.33M	2.73M	7M	7.62M
Fixed Asset Turnover	7.35x	6.37x	8.34x	12.86x	4.49x	4.86x
Goodwill	60.61K	64.65K	66.17K	61.14K	59.38K	57.77K
Intangible Assets	143.62K	107.23K	62.77K	49.48K	25.48K	16.53K
Long-Term Investments	0	0	-108.14K	-206.22K	-814.37K	0
Other Non-Current Assets	1.23M	951.01K	190.08K	5.81M	10.36M	8.14M
Total Assets+	11.76M	17.02M	26.12M	42.62M	56.71M	77.96M
Asset Turnover	1.04x	1.06x	1.06x	0.82x	0.55x	0.48x
Asset Growth %	-	0.45%	0.54%	0.63%	0.33%	0.37%
Total Current Liabilities+	33.61M	9.25M	9.77M	16.02M	18.98M	34.62M
Accounts Payable	100.25K	61.12K	340.21K	215.86K	550.19K	1.25M
Days Payables Outstanding	28.18	8.88	27.33	11.17	47.5	104.31
Short-Term Debt	28.09M	2.45M	2.04M	6.23M	8.17M	17.03M
Deferred Revenue (Current)	0	0	701.53K	692.51K	499.9K	792.1K
Other Current Liabilities	3.33M	5.41M	29.91K	20.32K	93.39K	45.24K
Current Ratio	0.26x	1.41x	2.29x	2.11x	2.11x	1.77x
Quick Ratio	0.24x	1.32x	1.98x	2.03x	2.05x	1.74x
Cash Conversion Cycle	307.52	274.65	382.01	313.32	416.57	462.69
Total Non-Current Liabilities+	728.29K	1M	494.12K	816.88K	2.03M	3.58M
Long-Term Debt	0	0	0	0	0	3.44M
Capital Lease Obligations	692.38K	974.29K	494.12K	816.88K	412.12K	136.68K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	35.9K	26.81K	0	0	1.61M	0
Total Liabilities	34.33M	10.25M	10.26M	16.84M	21M	38.2M
Total Debt+	28.94M	4.05M	2.93M	7.44M	9.9M	20.88M
Net Debt	28.72M	2.98M	-97.6K	5.73M	8.39M	17.91M
Debt / Equity	-	0.60x	0.61x	0.29x	0.28x	0.53x
Debt / EBITDA	4.86x	0.39x	0.22x	0.49x	0.77x	1.24x
Net Debt / EBITDA	4.82x	0.28x	-0.01x	0.38x	0.65x	1.06x
Interest Coverage	62.60x	61.84x	77.42x	45.55x	41.73x	26.55x
Total Equity+	-22.58M	6.76M	4.85M	25.78M	35.71M	39.76M
Equity Growth %	-	1.3%	-0.28%	4.32%	0.39%	0.11%
Book Value per Share	-3.14	0.94	0.67	3.59	4.71	1.55
Total Shareholders' Equity	-21.89M	7.21M	5.2M	25.93M	35.75M	39.66M
Common Stock	0	0	11.64K	2.94K	2.94K	2.56K
Retained Earnings	-15.67M	-9.62M	-7.13M	3.96M	14.39M	26.76M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-6.22M	16.83M	3.31M	3.12M	2.5M	1.45M
Minority Interest	-683.77K	-448.7K	-356.73K	-155.59K	-43.39K	101.34K

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	4.41M	3.91M	5.26M	485.97K	-1.02M	-6.31M
Operating CF Margin %	0.36%	0.22%	0.19%	0.01%	-0.03%	-0.17%
Operating CF Growth %	-	-0.11%	0.35%	-0.91%	-3.1%	-5.19%
Net Income	-7.18M	7.1M	10.18M	12.77M	10.55M	12.6M
Depreciation & Amortization	638.1K	1.07M	1.4M	1.47M	1.38M	1.51M
Stock-Based Compensation	0	0	0	0	0	0
Deferred Taxes	0	0	-45.38K	-143.32K	0	32.77K
Other Non-Cash Items	12.93M	-613.53K	286.05K	433.58K	1.11M	1.25M
Working Capital Changes	-1.98M	-3.65M	-6.57M	-14.05M	-14.05M	-21.7M
Change in Receivables	59.31K	-3.76M	-3.49M	-14.1M	-9.67M	-17.8M
Change in Inventory	-392.08K	-61.28K	-2.2M	1.57M	113.66K	-187.54K
Change in Payables	0	0	274.31K	-100.93K	0	727.8K
Cash from Investing+	1.18M	-2.17M	-1.39M	-5.92M	-2.64M	-2.85M
Capital Expenditures	-983.78K	-655.35K	-1.39M	-5.91M	-2.64M	-2.85M
CapEx % of Revenue	0.08%	0.04%	0.05%	0.17%	0.08%	0.08%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	2.17M	-1.52M	561	-12.16K	0	0
Cash from Financing+	-5.72M	-899.08K	-1.93M	4.41M	3.46M	10.72M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	-5.43M	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-5.32M	-629.46K	3.59M	-46.4K	1.11M	-2.49M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	3.43M	3.25M	3.87M	-5.47M	-3.66M	-9.17M
FCF Margin %	0.28%	0.18%	0.14%	-0.16%	-0.12%	-0.25%
FCF Growth %	-	-0.05%	0.19%	-2.41%	0.33%	-1.51%
FCF per Share	0.48	0.45	0.54	-0.76	-0.48	-0.36
FCF Conversion (FCF/Net Income)	-0.61x	0.55x	0.45x	0.04x	-0.10x	-0.51x
Interest Paid	92.78K	95.9K	90.08K	243.84K	261.32K	497.25K
Taxes Paid	0	0	3.91M	1.44M	0	1.84M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	104.97%	201.14%	82.08%	34.3%	33%
Return on Invested Capital (ROIC)	68.52%	93.13%	123.35%	56.4%	23.53%	22.57%
Gross Margin	89.37%	86.14%	83.61%	79.9%	86.56%	88.16%
Net Margin	-58.83%	39.18%	42.12%	35.82%	33.52%	33.62%
Debt / Equity	-	0.60x	0.61x	0.29x	0.28x	0.53x
Interest Coverage	62.60x	61.84x	77.42x	45.55x	41.73x	26.55x
FCF Conversion	-0.61x	0.55x	0.45x	0.04x	-0.10x	-0.51x
Revenue Growth	-	48.39%	52.99%	26.58%	-10.35%	17.74%

Frequently Asked Questions

Valuation & Price

Baird Medical Investment Holdings Limited (BDMD) has a price-to-earnings (P/E) ratio of 2.6x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Baird Medical Investment Holdings Limited (BDMD) reported $37.0M in revenue for fiscal year 2024. This represents a 203% increase from $12.2M in 2019.

Baird Medical Investment Holdings Limited (BDMD) grew revenue by 17.7% over the past year. This is strong growth.

Yes, Baird Medical Investment Holdings Limited (BDMD) is profitable, generating $12.5M in net income for fiscal year 2024 (33.6% net margin).

Dividend & Returns

Baird Medical Investment Holdings Limited (BDMD) has a return on equity (ROE) of 33.0%. This is excellent, indicating efficient use of shareholder capital.

Baird Medical Investment Holdings Limited (BDMD) had negative free cash flow of $9.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Baird Medical Investment Holdings Limited (BDMD) 10-Year Financial Performance & Capital Metrics

BDMD • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

Revenue $37M +17.7%
EBITDA $17M +30.6%
Net Income $12M +18.1%
EPS (Diluted) 0.49 +19.5%
Gross Margin 88.16% +1.9%
EBITDA Margin 45.42% +11.0%
Operating Margin 41.35% +9.7%
Net Margin 33.62% +0.3%
ROE 33% -3.8%
ROIC 22.57% -4.1%
Debt/Equity 0.53 +89.4%
Interest Coverage 26.55 -36.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 49.8%
✓Strong 5Y sales CAGR of 24.8%
✓Healthy 5Y average net margin of 36.9%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y24.85%

3Y10.14%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y2.17%

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg72.08%

5Y Avg72.79%

3Y Avg46.04%

Latest37.78%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	12.21M	18.12M	27.72M	35.09M	31.46M	37.04M
Revenue Growth %	-	0.48%	0.53%	0.27%	-0.1%	0.18%
Cost of Goods Sold+	1.3M	2.51M	4.54M	7.05M	4.23M	4.38M
COGS % of Revenue	0.11%	0.14%	0.16%	0.2%	0.13%	0.12%
Gross Profit+	10.91M	15.61M	23.18M	28.04M	27.23M	32.65M
Gross Margin %	0.89%	0.86%	0.84%	0.8%	0.87%	0.88%
Gross Profit Growth %	-	0.43%	0.48%	0.21%	-0.03%	0.2%
Operating Expenses+	5.3M	5.75M	9.76M	13.03M	15.37M	17.34M
OpEx % of Revenue	0.43%	0.32%	0.35%	0.37%	0.49%	0.47%
Selling, General & Admin	4.15M	5M	10.22M	10.55M	11.09M	9.96M
SG&A % of Revenue	0.34%	0.28%	0.37%	0.3%	0.35%	0.27%
Research & Development	1.16M	750.48K	1.04M	3.86M	4.27M	6.17M
R&D % of Revenue	0.09%	0.04%	0.04%	0.11%	0.14%	0.17%
Other Operating Expenses	0	0	0	0	0	1.2M
Operating Income+	5.61M	9.86M	11.92M	13.63M	11.86M	15.32M
Operating Margin %	0.46%	0.54%	0.43%	0.39%	0.38%	0.41%
Operating Income Growth %	-	0.76%	0.21%	0.14%	-0.13%	0.29%
EBITDA+	5.96M	10.47M	13.32M	15.1M	12.88M	16.82M
EBITDA Margin %	0.49%	0.58%	0.48%	0.43%	0.41%	0.45%
EBITDA Growth %	-	0.76%	0.27%	0.13%	-0.15%	0.31%
D&A (Non-Cash Add-back)	349.14K	609.55K	1.4M	1.47M	1.01M	1.51M
EBIT	5.5M	9.67M	12.76M	14.82M	11.86M	14.66M
Net Interest Income+	-89.62K	-159.47K	-151.59K	-290.72K	-284.27K	-576.36K
Interest Income	0	0	2.33K	8.55K	0	393
Interest Expense	89.62K	159.47K	153.92K	299.27K	284.27K	576.75K
Other Income/Expense	-11.46M	-283.25K	688.35K	890.15K	497.48K	-1.23M
Pretax Income+	-5.85M	9.58M	12.61M	14.52M	12.36M	14.09M
Pretax Margin %	-0.48%	0.53%	0.45%	0.41%	0.39%	0.38%
Income Tax+	1.28M	2.43M	2.42M	1.75M	1.7M	1.49M
Effective Tax Rate %	1.23%	0.74%	0.93%	0.87%	0.85%	0.88%
Net Income+	-7.18M	7.1M	11.68M	12.57M	10.55M	12.45M
Net Margin %	-0.59%	0.39%	0.42%	0.36%	0.34%	0.34%
Net Income Growth %	-	1.99%	0.64%	0.08%	-0.16%	0.18%
Net Income (Continuing)	-7.13M	7.15M	10.18M	12.77M	10.66M	12.6M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	-683.77K	-448.7K	-356.73K	-155.59K	-43.39K	101.34K
EPS (Diluted)+	-1.00	0.99	-0.02	0.02	0.41	0.49
EPS Growth %	-	1.99%	-1.02%	1.9%	17.89%	0.2%
EPS (Basic)	-1.00	0.99	-0.02	0.02	0.41	0.49
Diluted Shares Outstanding	7.19M	7.19M	7.19M	7.19M	7.58M	25.63M
Basic Shares Outstanding	7.19M	7.19M	7.19M	6.29M	7.58M	25.56M
Dividend Payout Ratio	-	-	0.46%	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.67M	13.05M	22.4M	33.76M	40.08M	61.42M
Cash & Short-Term Investments	257.08K	1.14M	3.44M	1.91M	1.63M	2.97M
Cash Only	220.45K	1.07M	3.03M	1.71M	1.51M	2.97M
Short-Term Investments	36.62K	65.11K	407.5K	197K	120.48K	0
Accounts Receivable	4.56M	8.23M	12.45M	24.76M	31.49M	46.58M
Days Sales Outstanding	136.28	165.78	163.89	257.58	365.42	459.03
Inventory	709.47K	810.07K	3.06M	1.29M	1.14M	1.3M
Days Inventory Outstanding	199.41	117.75	245.44	66.91	98.65	107.97
Other Current Assets	3.05M	620.89K	304.29K	197K	120.48K	295.75K
Total Non-Current Assets+	3.09M	3.97M	3.72M	8.85M	16.63M	16.55M
Property, Plant & Equipment	1.66M	2.84M	3.33M	2.73M	7M	7.62M
Fixed Asset Turnover	7.35x	6.37x	8.34x	12.86x	4.49x	4.86x
Goodwill	60.61K	64.65K	66.17K	61.14K	59.38K	57.77K
Intangible Assets	143.62K	107.23K	62.77K	49.48K	25.48K	16.53K
Long-Term Investments	0	0	-108.14K	-206.22K	-814.37K	0
Other Non-Current Assets	1.23M	951.01K	190.08K	5.81M	10.36M	8.14M
Total Assets+	11.76M	17.02M	26.12M	42.62M	56.71M	77.96M
Asset Turnover	1.04x	1.06x	1.06x	0.82x	0.55x	0.48x
Asset Growth %	-	0.45%	0.54%	0.63%	0.33%	0.37%
Total Current Liabilities+	33.61M	9.25M	9.77M	16.02M	18.98M	34.62M
Accounts Payable	100.25K	61.12K	340.21K	215.86K	550.19K	1.25M
Days Payables Outstanding	28.18	8.88	27.33	11.17	47.5	104.31
Short-Term Debt	28.09M	2.45M	2.04M	6.23M	8.17M	17.03M
Deferred Revenue (Current)	0	0	701.53K	692.51K	499.9K	792.1K
Other Current Liabilities	3.33M	5.41M	29.91K	20.32K	93.39K	45.24K
Current Ratio	0.26x	1.41x	2.29x	2.11x	2.11x	1.77x
Quick Ratio	0.24x	1.32x	1.98x	2.03x	2.05x	1.74x
Cash Conversion Cycle	307.52	274.65	382.01	313.32	416.57	462.69
Total Non-Current Liabilities+	728.29K	1M	494.12K	816.88K	2.03M	3.58M
Long-Term Debt	0	0	0	0	0	3.44M
Capital Lease Obligations	692.38K	974.29K	494.12K	816.88K	412.12K	136.68K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	35.9K	26.81K	0	0	1.61M	0
Total Liabilities	34.33M	10.25M	10.26M	16.84M	21M	38.2M
Total Debt+	28.94M	4.05M	2.93M	7.44M	9.9M	20.88M
Net Debt	28.72M	2.98M	-97.6K	5.73M	8.39M	17.91M
Debt / Equity	-	0.60x	0.61x	0.29x	0.28x	0.53x
Debt / EBITDA	4.86x	0.39x	0.22x	0.49x	0.77x	1.24x
Net Debt / EBITDA	4.82x	0.28x	-0.01x	0.38x	0.65x	1.06x
Interest Coverage	62.60x	61.84x	77.42x	45.55x	41.73x	26.55x
Total Equity+	-22.58M	6.76M	4.85M	25.78M	35.71M	39.76M
Equity Growth %	-	1.3%	-0.28%	4.32%	0.39%	0.11%
Book Value per Share	-3.14	0.94	0.67	3.59	4.71	1.55
Total Shareholders' Equity	-21.89M	7.21M	5.2M	25.93M	35.75M	39.66M
Common Stock	0	0	11.64K	2.94K	2.94K	2.56K
Retained Earnings	-15.67M	-9.62M	-7.13M	3.96M	14.39M	26.76M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-6.22M	16.83M	3.31M	3.12M	2.5M	1.45M
Minority Interest	-683.77K	-448.7K	-356.73K	-155.59K	-43.39K	101.34K

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	4.41M	3.91M	5.26M	485.97K	-1.02M	-6.31M
Operating CF Margin %	0.36%	0.22%	0.19%	0.01%	-0.03%	-0.17%
Operating CF Growth %	-	-0.11%	0.35%	-0.91%	-3.1%	-5.19%
Net Income	-7.18M	7.1M	10.18M	12.77M	10.55M	12.6M
Depreciation & Amortization	638.1K	1.07M	1.4M	1.47M	1.38M	1.51M
Stock-Based Compensation	0	0	0	0	0	0
Deferred Taxes	0	0	-45.38K	-143.32K	0	32.77K
Other Non-Cash Items	12.93M	-613.53K	286.05K	433.58K	1.11M	1.25M
Working Capital Changes	-1.98M	-3.65M	-6.57M	-14.05M	-14.05M	-21.7M
Change in Receivables	59.31K	-3.76M	-3.49M	-14.1M	-9.67M	-17.8M
Change in Inventory	-392.08K	-61.28K	-2.2M	1.57M	113.66K	-187.54K
Change in Payables	0	0	274.31K	-100.93K	0	727.8K
Cash from Investing+	1.18M	-2.17M	-1.39M	-5.92M	-2.64M	-2.85M
Capital Expenditures	-983.78K	-655.35K	-1.39M	-5.91M	-2.64M	-2.85M
CapEx % of Revenue	0.08%	0.04%	0.05%	0.17%	0.08%	0.08%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	2.17M	-1.52M	561	-12.16K	0	0
Cash from Financing+	-5.72M	-899.08K	-1.93M	4.41M	3.46M	10.72M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	-5.43M	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-5.32M	-629.46K	3.59M	-46.4K	1.11M	-2.49M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	3.43M	3.25M	3.87M	-5.47M	-3.66M	-9.17M
FCF Margin %	0.28%	0.18%	0.14%	-0.16%	-0.12%	-0.25%
FCF Growth %	-	-0.05%	0.19%	-2.41%	0.33%	-1.51%
FCF per Share	0.48	0.45	0.54	-0.76	-0.48	-0.36
FCF Conversion (FCF/Net Income)	-0.61x	0.55x	0.45x	0.04x	-0.10x	-0.51x
Interest Paid	92.78K	95.9K	90.08K	243.84K	261.32K	497.25K
Taxes Paid	0	0	3.91M	1.44M	0	1.84M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	104.97%	201.14%	82.08%	34.3%	33%
Return on Invested Capital (ROIC)	68.52%	93.13%	123.35%	56.4%	23.53%	22.57%
Gross Margin	89.37%	86.14%	83.61%	79.9%	86.56%	88.16%
Net Margin	-58.83%	39.18%	42.12%	35.82%	33.52%	33.62%
Debt / Equity	-	0.60x	0.61x	0.29x	0.28x	0.53x
Interest Coverage	62.60x	61.84x	77.42x	45.55x	41.73x	26.55x
FCF Conversion	-0.61x	0.55x	0.45x	0.04x	-0.10x	-0.51x
Revenue Growth	-	48.39%	52.99%	26.58%	-10.35%	17.74%

Frequently Asked Questions

Valuation & Price

Baird Medical Investment Holdings Limited (BDMD) has a price-to-earnings (P/E) ratio of 2.6x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Baird Medical Investment Holdings Limited (BDMD) reported $37.0M in revenue for fiscal year 2024. This represents a 203% increase from $12.2M in 2019.

Baird Medical Investment Holdings Limited (BDMD) grew revenue by 17.7% over the past year. This is strong growth.

Yes, Baird Medical Investment Holdings Limited (BDMD) is profitable, generating $12.5M in net income for fiscal year 2024 (33.6% net margin).

Dividend & Returns

Baird Medical Investment Holdings Limited (BDMD) has a return on equity (ROE) of 33.0%. This is excellent, indicating efficient use of shareholder capital.

Baird Medical Investment Holdings Limited (BDMD) had negative free cash flow of $9.2M in fiscal year 2024, likely due to heavy capital investments.